192 related articles for article (PubMed ID: 11699607)
1. Availability of medicines in the European Union: results from the EURO-Medicines project.
Folino-Gallo P; Walley T; Frolich JC; Carvajal A; Edwards IR
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):441-6. PubMed ID: 11699607
[TBL] [Abstract][Full Text] [Related]
2. EURO-MED-STAT: monitoring expenditure and utilization of medicinal products in the European Union countries: a public health approach.
EURO-MED STAT Group
Eur J Public Health; 2003 Sep; 13(3 Suppl):95-100. PubMed ID: 14533757
[TBL] [Abstract][Full Text] [Related]
3. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
Brion F; Nunn AJ; Rieutord A
Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
[TBL] [Abstract][Full Text] [Related]
4. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
5. Patient Access to Medicines for Rare Diseases in European Countries.
Detiček A; Locatelli I; Kos M
Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
[TBL] [Abstract][Full Text] [Related]
6. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
7. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries.
Post HC; Schutte T; van Oijen MGH; van Laarhoven HWM; Hollak CEM
ESMO Open; 2023 Apr; 8(2):101208. PubMed ID: 37030113
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Medicine Prices in New Zealand and 16 European Countries.
Vogler S; Kilpatrick K; Babar ZU
Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
[TBL] [Abstract][Full Text] [Related]
9. OTC market - comparing Czech Republic and Greece.
Macešková B; Tsadaris MP; Machlis M
Ceska Slov Farm; 2019; 68(2):78-85. PubMed ID: 31331177
[TBL] [Abstract][Full Text] [Related]
10. Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.
Zeitoun JD; Lefèvre JH; Downing N; Bergeron H; Ross JS
PLoS One; 2014; 9(10):e109100. PubMed ID: 25333986
[TBL] [Abstract][Full Text] [Related]
11. European regulatory policies on medicines and public health needs.
Li Bassi L; Bertele V; Garattini S
Eur J Public Health; 2003 Sep; 13(3):246-51. PubMed ID: 14533728
[TBL] [Abstract][Full Text] [Related]
12. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
13. [ATC classification: lights and shadows].
Bosone E; Secondi A
Boll Chim Farm; 1990 Apr; 129(4):169-72. PubMed ID: 2245006
[TBL] [Abstract][Full Text] [Related]
14. The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand.
Aaltonen K; Ragupathy R; Tordoff J; Reith D; Norris P
Value Health; 2010; 13(1):148-56. PubMed ID: 19744294
[TBL] [Abstract][Full Text] [Related]
15. Is parallel trade in medicines compatible with the single European market?
Senior I
Pharmacoeconomics; 1992; 1(Suppl 1):70-6. PubMed ID: 10172047
[TBL] [Abstract][Full Text] [Related]
16. Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA.
Bajcetic M; Kearns GL; Jovanovic I; Brajovic M; van den Anker JN
Curr Pharm Des; 2015; 21(39):5668-73. PubMed ID: 26323413
[TBL] [Abstract][Full Text] [Related]
17. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
Pashkov V; Soloviov A; Olefir A
Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
[TBL] [Abstract][Full Text] [Related]
18. [The characteristics of regulation of pharmaceutical market of the Eurasian Economical Union].
Marseva TG; Voblaia IN; Seifieva EN
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2019 Sep; 27(5):841-846. PubMed ID: 31765534
[TBL] [Abstract][Full Text] [Related]
19. The drug market in four European countries.
Garattini S
Pharmacoeconomics; 1998; 14 Suppl 1():69-79. PubMed ID: 10186484
[TBL] [Abstract][Full Text] [Related]
20. Industry Perspective of Pediatric Drug Development in the United States: Involvement of the European Union Countries.
Onishi T; Tsukamoto K; Matsumaru N; Waki T
Ther Innov Regul Sci; 2018 Jan; 52(1):49-56. PubMed ID: 29714619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
